Enrollment Complete in Landmark Clinical Trial and Modular PMA Initiated
December 9, 2014
Intrinsic Therapeutics, a medical device company focused on treating lumbar disc herniations, announced that patient enrollment is now complete in the company's randomized superiority clinical trial of the Barricaid® anular closure device, and the first of four PMA modules has been submitted to the FDA. Weiter lesen »
Intrinsic raising $21M for implant to improve lumbar disc surgery
September 18, 2014
Effective surgical elimination of back pain is a sensitive subject, as it's so difficult to achieve. But one company may be hitting that mark. It's aiming at more effective surgical treatment of lumbar disc herniation and is in the process of raising almost $21 million in venture capital, according to a Sept. 17 SEC filing. Weiter lesen »
Barricaid® iPad App Now Available Through iTunes Store!
April 10, 2013
Barricaid Surgical Training application (App) for the iPad is now available to download free of charge from the iTunes App Store. The app is designed to support user training and provide reference for Intrinsic Therapeutics’ Barricaid®, Prosthesis for Partial Anulus Replacement, and its accompanying system for replacing missing or damaged parts of the posterior anulus fibrosus in intervertebral lumber discs.The app is designed to support user training and provide reference for Intrinsic Therapeutics’ Barricaid®, Prosthesis for Partial Anulus Replacement, and its accompanying system for replacing missing or damaged parts of the posterior anulus fibrosus in intervertebral lumber discs. Use of the applications will provide surgeons with hands-on preoperative and intraoperative procedural guidance and training for proper clinical treatment using the Barricaid system. We greatly appreciate any feedback on lay-out, ease of use, functionality, descriptions etc. Currently, the app is only available in iPad format and will not show up if searching on an iPhone. Weiter lesen »
Verschluss von Anulusdefekten mit der Barricaid®-Anulus-Teilersatz
3. Januar 2013
Diskektomien führen oft nur kurzfristig zum Erfolg. Bei aggressiver Entfernung des Nukleus steigt das Risiko für einen Bandscheibenkollaps, bei der schonenden partiellen Diskektomie erhöht sich das Risiko für ein Prolapsrezidiv. Die Bandscheiben-Teilendoprothese Barricaid® verschließt den Anulusdefekt und ermöglicht so, den Nukleus weitgehend zu erhalten. Bei einem Symposium von Intrinsic Therapeutics im Rahmen des 7. Deutschen Wirbelsäulen-Kongresses diskutierten Spezialisten verschiedener Disziplinen, inwieweit Barricaid® nachhaltig Rezidiven vorbeugen, die Bandscheibenhöhe und damit die Biomechanik erhalten kann.
Weiter lesen »
Intrinsic at the Annual Meeting of the German Society of Neurosurgery (DGNC)
June 16, 2012
Barricaid® Prosthesis for Anular Closure is an important thematic focal point of the 63rd Annual Meeting of the German Society of Neurosurgery. On June 16, 2012, 4 papers dealing with the clinical results of Barricaid were presented, which include, among others, 2-year results coming from a multinational clinical study.
Intrinsic Therapeutics, Inc. Names Cary P. Hagan as President & CEO
August 15, 2011
Intrinsic Therapeutics, a medical device company focused on developing therapies to address the spine market’s many unmet needs, today announced that Cary Hagan has been appointed President and Chief Executive Officer. Mr. Hagan brings over 20 years of experience in the orthopedic implant field with significant expertise in product development, commercialization and global marketing strategy. Greg Lambrecht, Founder and Board Member of Intrinsic, is actively continuing at the company as Executive Director